Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 82.9%

Neg 0% Neu 82.9% Pos 0%

Needham analyst Ami Fadia reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $50 price target.

Comments

No comments yet. Be the first!